OBJECTIVES: To measure utility (risk preference) of individuals deciding to take a multiple sclerosis (MS) drug given varying risks/benefi ts. METHODS: A computerized measure based on ProSPEQT software was developed to measure Standard Gamble utility. 45 healthy individuals were presented with 9 health states varying MS disease severity (mild, moderate, severe) and asked their preferences to remain in that state or gamble on taking a drug with varying probabilities of 3 levels of MS improvements (mild, average, substantial) but also corresponding probabilities of death. Student's t-test analyzed affects of gender, age-groups, education, and MS experience on utility. RESULTS: Subjects ranged from 16-69 years (mean 40 years) and 44.4% knew someone with MS. In general, healthy individuals were willing to accept substantial risk of death for even mild MS improvements and accepted more risk for severe MS and greater disease improvements. The lowest mean score was for mild MS improvement given mild MS (0.082; 95% CI [0.045-0.120]). The highest score was for substantial MS improvement given severe MS (0.382;). Only education signifi cantly affected utility for mild improvement in mild MS (p 0.03). Individuals with bachelor's degree or less had 7.7% higher score than post-graduates. CONCLUSIONS: We found it surprising how much risk of death healthy individuals were willing to accept (8-38%). This is much greater than the 1/1000 actual risk for natalizumab in MS treatment, which the FDA removed from the market. MS patients' voiced preferences helped get that drug back on the market, showing importance of shared health decision-making. The FDA and physicians might fi nd it diffi cult to approve or prescribe drugs with 38% risk of death. However, these preferences indicate healthy individuals may be less risk-averse than the FDA or physicians, emphasizing the importance of including the public when weighing risks and benefi ts of drugs.
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RISK OF DIABETES ASSOCIATED WITH THE USE OF ATYPICAL ANTIPSYCHOTICS IN CHILDREN AND ADOLESCENTS -A TEXAS MEDICAID STUDY
Nagar SP g , Mehta S, Zweifel P, Chen H P P University of Houston, Houston, TX, USA OBJECTIVES: To examine the risk of developing diabetes among children and adolescents who received atypical antipsychotic drug. METHODS: This study is a retrospective cohort analysis using [2003] [2004] Texas Medicaid claims data. Patients were included in the cohort if they met the following criteria: 6 to 18 years of age, new users of atypical antipsychotics and had not received a diagnosis of diabetes (ICD-9-CM code: 250.xx) or a prescription claim of an anti-diabetic drug both before and one month after the initiation of an antipsychotic treatment. Risk of newly developed diabetes following antipsychotic treatment was observed during a 12 month follow-up period. Kaplan-Meier survival curves and Cox proportional-hazards regression model were employed to examine the time dependent risk (hazard) of diabetes and hazards ratio were obtained. Age, gender, race and exposure to other diabetogenic medications were controlled in the analysis. RESULTS: A total of 4096 patients were identifi ed as new atypical antipsychotic users. The average age of the cohort was 11 years, most of the patients were male (65%), and Hispanics (36.5%). Cox-proportional hazard model analysis revealed no signifi cant association between use of atypical antipsychotic use and risk of diabetes (Hazards Ratio, HR 1.11, 95% CI 0.81-1.53). Children in the older age group of 15-18 years, females and Hispanics had higher risk of developing diabetes. Concurrent treatments with corticosteroids, beta-blockers, thiazides and antidepressants were also associated with increased incidence of diabetes. CONCLUSIONS: Our results indicate that there is no increase in the risk of developing diabetes in pediatric patients receiving atypical antipsychotics. The discrepancy in the fi ndings between adults and children implies that psychotropic medications might function differently in pediatric population from adults. It is necessary to comprehensively assess the risks associated with common off-label medications, such as atypical antipsychotics, in children and adolescents.
RA3 A BAYESIAN DECISION-ANALYTIC ECONOMIC MODEL TO OPTIMIZE ALLOCATION OF RISK IN PAY-FOR-PERFORMANCE PAYMENT ARRANGEMENTS
Mallick R 1 , Hollenbeak C 2 1 Risk Sharing Solutions, Collegeville, PA, USA, 2 Penn State College of Medicine, Hershey, PA, USA OBJECTIVES: Performance-based payment arrangements for innovative drugs seek to allocate fi nancial risk of interventions between manufacturers and payers. Given operational challenges in monitoring real-world outcomes, effective risk sharing mechanisms may require prediction of incremental survival/quality-adjusted life years (QALYs) conditional on surrogate markers, for example, complete remission (CR) or partial remission (PR). In accepting a risk-sharing arrangement that reimburses only for remitters, payers should minimize the "false-positive" (FP) risk: early remitters who subsequently have limited QALYs. Manufacturers should minimize the "falsenegative" (FN) risk: early non-remitters who subsequently have prolonged QALYs.
A Bayesian decision framework can be used to choose among multiple likelihood (predictive) priors to optimize the posterior economic risk trade-off for payers and manufacturers. METHODS: A Bayesian decision-analytic, hypothetical data-based, cost-effectiveness model was developed. Prior probabilities and QALYs were assigned for 6-, 3-, and 1-month survival, as were treatment costs. A plausible prior likelihood (predictive) structure represented the (ROC) relationship between the sensitivity and specifi city of CR/PR in predicting survival. Expected (posterior) probabilities of survival, conditional on CR/PR, were generated. At a threshold of $50,000/QALY, the cost-effectiveness of the intervention, conditional on achieving CR/PR, and an optimal sensitivity-specifi city trade-off was derived. RESULTS: At a hypothetical treatment cost of $5,000/month for a 4-month cycle, a minimal FP of 13% (maximum specifi city of 87%) and a minimal FN of 33% (maximum sensitivity of 67%) emerged as necessary to be accepted by payers and manufacturers respectively to ensure viable risksharing. At higher sensitivity, payer risk did not meet the reimbursement threshold, while at higher specifi city, manufacturers would assume excessive fi nancial risk. Other illustrations will be discussed. CONCLUSIONS: Manufacturers should propose evidence-based payment arrangements that utilize clinical trial data to develop economic implications of being at various points on the ROC curve in order to optimize the trade-offs between payer and manufacturer incentives.
RA4 METABOLIC SYNDROME RISK FACTORS FOR NATIVE BORN AND FIRST GENERATION ADOLESCENTS (12-17) IN THE UNITED STATES
Hufstader MA 1 , Sias S 1 , Vaidya V 2 , White-Means S 1 1 University of Tennessee Health Science Center, Memphis, TN, USA, 2 University of Tennessee, Memphis, TN, USA OBJECTIVES: To contrast the factors that are associated with metabolic syndrome risk for both adolescents overall and Hispanic adolescents in the U.S. METHODS: At risk is defi ned as having three or more of the following: elevated fasting glucose, elevated SBP, elevated DBP, elevated triglycerides, elevated BMI, elevated waist circumference, or low HDL. Logistic regression and NHANES 2003-2006 data were used to examine the impact on metabolic syndrome risks; gender, race, ethnicity, immigrant status, income, insurance, parental education, activity levels, number of school lunches and breakfasts per week, milk consumption, language preference, and number of meals outside the home per week. Adolescents in the United States overall are compared with Hispanic adolescents in the U.S. A signifi cance level of 0.05 was used. Weighted sample sizes for Hispanic adolescents and adolescents in the U.S. are 8,178,714, and 50,837,204 . RESULTS: Major differences include the decreased risk (42%) for adolescent females overall in the U. S., and the increased risk (17%) for Hispanic females in the U.S. Notably, for those Hispanics that are fi rst generation, their risk is increased by 65%. For adolescents overall in the U.S., low or middle income levels increase risk three times, while low and middle income level Hispanic adolescents in the U.S. have a risk decrease of 77% and 69% respectively. For every meal eaten outside the home per week (excluding school meals) the risk increases for adolescents in the U.S. by 4% and by 13% for Hispanic adolescents in the U.S. CONCLUSIONS: These adolescents are at risk for acute cardiovascular endpoints, higher medical utilization and expenditure, and lower quality of life. Interventions should focus on education regarding healthy eating outside the home with limited resources. This analysis is the high price of acculturation for Hispanic fi rst generation adolescents. Previous research has shown that high utilization of short-actingagonists (SABA) is associated with asthma exacerbations, however annual assessments present signifi cant barriers to real-time assessment needed for effective intervention. We explored a quarterly assessment of high SABA utilization patterns on subsequent asthma exacerbations. METHODS: A retrospective cohort study conducted using PHARMetrics database included health plan members (aged 6-56 years; n 93,604) with asthma and two-year continuous enrollment between 7/2003-6/2007, 1 hospitalization/emergency department (ED) or 2 outpatient claims of International Classifi cation of Diseases, 9th Revision, Clinical Modifi cation (ICD-9-CM) code 493.XX and 1 asthma medication claim in each of the two years of observation. Patients with COPD and diseases associated with chronic oral steroid use were excluded. SABA utilization was converted to canister-count in their fi rst observed quarter and categorized into 0, ½-1, 1½-2, 2. Risk of an asthma exacerbation in the subsequent quarter, defi ned as an oral steroid claim, hospitalization, or ED visit, was assessed using logistic regression, controlling for age, sex, region, and several fi rst-quarter severity measures/ comorbidities. RESULTS: The cohort included 33,951 patients aged 6-17 (36%) and 59653 aged 18-56 (64%) of which 64% had 0 SABA canisters, 18% had ½-1, 9% had 1½-2, and 9% had 2. Compared to 0 canisters, higher SABA utilization was associated with higher exacerbation risk [½-1 (OR:1.01; CI:0.92-1.12), 1½-2
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